

# MSC: 20<sup>th</sup> Anniversary JSM Memorial Education Forum

### Agenda for our discussion today


### ResMed 2025 Mission

- ResMed 2025 Strategy
  - Sleep Apnea
  - COPD
  - Software-as-a-Service
  - Digital Health Technology
- Open Forum Q&A



### Our mission is to change 250 million lives in 2025

We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice



### ResMed 2025: a patient-centric, digitally-enabled strategy

### Expect impact of COVID-19 will accelerate this strategy



250 million lives improved in out-of-hospital healthcare in 2025!


and higher quality lives in the comfort of their home

**Growth Focus** • Global health epidemics in sleep apnea, COPD, other major chronic conditions, and SaaS solutions that improve care in out-of-hospital settings

**Growth Advantage** ◆ Transform care through innovative solutions and tech-driven integrated care to drive superior outcomes, experiences and efficiency


**Growth Foundations** ♦ High-performing, diverse and entrepreneurial people

- Industry-leading innovation and business excellence
- Digital health technology and scientific leadership





### Priorities that guide our daily focus




Empower people to live happier, healthier and higher quality lives in the comfort of their homes



## Sleep Apnea



### The global prevalence of sleep apnea is enormous and growing...





### Our partnerships will address sleep health as a public health crisis



### Sleep research joint venture with Verily

 Develop software solutions to help identify, diagnose, treat, and manage those with OSA



- To study the health and financial impacts of untreated sleep apnea
  - Prove the ROI for treating OSA



With Verily, we can unlock richer, more holistic insights about sleep apnea and the value of treating it




### Reducing mortality with PAP therapy

### U.S. multicenter, population-based cohort study



- Study included 392 patients with sleep apnea, with 11 years of follow-up
- Positive airway pressure therapy associated with a 62% lower risk of all-cause mortality
- Death rate was twice as high for persons who did not receive positive airway pressure therapy
  - (24.7 vs 12.8 deaths per 1000 person years, p = 0.03)





## Demonstrated positive dose-response relationship between increased CPAP usage and lower healthcare costs

For every one hour per night increase in PAP usage there was an 8% decrease in inpatient visits and a 4% decrease in overall acute care visits.<sup>1</sup>



<sup>1.</sup> Kirsch et al., Association of PAP use with acute care utilization and costs, JCSM 2019 "Overall visits" includes inpatient, ED, and observation visits.



## COPD



### COPD is one of the top three killers in the world with no cure

### COPD has causes from environmental, to occupational, to genetics


### Causes include:

- smoking, vaping, & second hand smoke
- air pollution from industry and transportation
- occupational exposure to noxious gases

- history of childhood infections (catalyst)
- genetic inheritance, leading to COPD onset














### COPD is a large and growing market



- More than 380 million people worldwide are estimated to have COPD
  - -Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil and E. Europe may be well over 100 million
- Cost to healthcare systems from COPD is enormous:
  - –Europe: ~€48 billion per year
  - -United States: ~\$50 billion per year
- More than 3 million people worldwide die each year due to COPD





<sup>&</sup>lt;sup>1</sup>World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20Jul16

<sup>&</sup>lt;sup>2</sup> https://www.ncbi.nlm.nih.gov/pubmed/26755942

<sup>&</sup>lt;sup>3</sup> Company estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" Respiratory and Critical Care

<sup>&</sup>lt;sup>4</sup> European Respiratory Society, European Lung White Book http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/accessed 20Jul16

<sup>&</sup>lt;sup>5</sup> Guarascio et al. Dove Med Press, 2013 Jun 17

<sup>&</sup>lt;sup>6</sup> World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact sheet No315. 2015 accessed 20Jul16

### Our digital health platform supports COPD patients on their healthcare journey

The digital respiratory Integrated Care Model we are creating through Propeller

Data processed by a powerful insights engine

**Driving value propositions** for stakeholders





**Machine** Learning



Order telehealth consultation



**Exacerbation alert** 



Clinician decision support (e.g., recommend POC)



Pollen alert




Clinical data for patients / clinicians




Recommend rehab



**Order test** 





The Integrated Care Model will support patients through their journey of chronic respiratory diseases

## Software as a Service (SaaS)



### SaaS portfolio well positioned to improve outcomes and lower costs across out-of-hospital healthcare

Better patient experience. Improved clinical outcomes. Lower overall cost of care.


- Intelligent workflow
- **Privacy**
- Security
- Advanced analytics
- Interoperability

- Single view of the patient
- Comprehensive interoperability
- Care transition, coordination, and collaboration
- Seamless access to information for patients and those who care for them
- Manage populations across provider / care settings
- Data insights to enable better care / better results

Connected systems deliver the best outcomes for value-based care



### Leading provider of cloud-based software for out-of-hospital care providers across multiple settings






## Digital Health Technology



### Digital health technology — our transformational foundation


Enable <u>all</u> ResMed businesses to achieve their business objectives Purpose: by leveraging technology, data, and advanced analytics.





### We transform 7.5+ billion nights of medical data into useful outcomes

### End-to-end connected health solutions in sleep, respiratory care, and out-of-hospital healthcare



### Global leadership in digital health

AirView<sup>TM</sup> has over

14 million patients

1 million+ diagnostic tests processed in the cloud

~100 API calls per second from integrators

>12 million
100% cloud connectable
devices worldwide

100+ million accounts in out-of-hospital care network

2.5 million+ patients have signed up for myAir™




### Turning big data into actionable information

Pioneering *innovation* and providing *clinical evidence* that support better patient outcomes and improved business efficiencies for customers











World's largest study for adherence

> 128,000 patients



patient adherence with automated compliance coaching<sup>1</sup>

<sup>1.</sup> Hwang, et al., AJRCCM 2017

<sup>2.</sup> Munafo, et al. Sleep Breath 2016


<sup>3.</sup> Data based on monthly patient setups and compliance rates of DME customers from February 2014 – March 2015. Historical results for this provider over the stated time

Crocker, et al., Abstract CHEST 2016

### Improving adherence to therapy with patient monitoring and resupply

### ResAdhere: remote monitoring + mask resupply drive improved adherence

In a study of ~100k patients with AirView cloud-connected devices...




...the likelihood of therapy termination decreased by >50% after one-year and there was a significant increase in daily PAP usage



### Big data analysis drives insights for treatment of central sleep apnea

### Patients with treatment-emergent central sleep apnea (CSA) are 2x more likely to terminate therapy

- Opportunity to rethink conventional therapeutic options
- Minimize risk of therapy termination through early diagnosis
- Regularly monitor patients to support adherence to treatment






- Switching from therapy CPAP to ASV improved relative adherence by 22%
- Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep



### Digital health solutions for inhaled COPD pharmaceuticals

- ResMed now has end-to-end solutions for Digital Health for COPD patients across stages I, II, III, IV of the disease
- Uses sensors with inhalers to track medication usage and provide personal feedback and insights
- Establishes ResMed as a leading provider of COPD and asthma patient management solutions
- Enables digitally-enabled integration of care through the progression of the disease







**Patient Acquisition** 





represent 90% of long-acting respiratory inhalation drugs


### Propeller has demonstrated compelling clinical outcomes




### Impact of the Propeller solution tracking inhaler usage and location












QoL: Rescue Inhaler use per day

### Healthcare utilization




Drives a reduction in healthcare utilization






**Adherence** 



### Acute care utilization


### Events per 100 patient years



Drives a reduction in healthcare utilization




### Our digital health solutions improve outcomes and lower costs





## In the last 12 months, we changed over 115 million lives with our digital health products and cloud-based software solutions



## APPENDIX



### Our response to COVID-19: Focused on preservation of life

### **Our ResMed Team**

- Work-from-home policy for all employees when job can be performed remotely
- Specific actions to protect and support employees working in our manufacturing and distribution sites, including:
  - split shifts (A/B/C)
  - increased cleaning, personal hygiene, and safety protocols including temperature checks
  - personal protective equipment for all staff (PPE)
- Increased cadence of communications and engagement with employees

### **Our Stakeholders**

- Fair and ethical allocation of products globally supported by an epidemiological model
- Transitioned manufacturing lines to support production of ventilation products to meet global demand
  - Tripled manufacturing of ventilators
  - Scaled up ventilation mask production more than 10x
- Updated and ongoing clinical information
- Increased digital health technology and remote patient care services for customers

### **Business Continuity**

- Established key workstreams and a central task force to guide and manage ResMed through the crisis
- Ongoing communication with suppliers and partners to ensure continuity and identify gaps
- Active engagement with key government officials and healthcare systems worldwide
- Ongoing business modeling and scenario planning
- Prudent cash and expense management

